Table 2.
Genotype frequencies of VEGF gene polymorphisms between controls and RPL patients.
| Genotype | Controls (n = 236) | RPL Patients (n = 378) | AOR (95% CI) | p a | p b |
|---|---|---|---|---|---|
| VEGF 1451C>T | |||||
| CC | 166 (70.3) | 242 (64.0) | 1.000 (reference) | ||
| CT | 61 (25.8) | 126 (33.3) | 1.406 (0.977–2.024) | 0.067 | 0.067 |
| TT | 9 (3.8) | 10 (2.7) | 0.783 (0.310–1.977) | 0.605 | 0.908 |
| Dominant (CC vs. CT+TT) | 1.324 (0.933–1.879) | 0.116 | 0.116 | ||
| Recessive (CC+CT vs. TT) | 0.693 (0.277–1.734) | 0.433 | 0.650 | ||
| C allele | 393 (83.3) | 610 (80.7) | 1.000 (reference) | ||
| T allele | 79 (16.7) | 146 (19.3) | 1.187 (0.877–1.605) | 0.267 | 0.267 |
| HWE P | 0.265 | 0.176 | |||
| VEGF 1612G > A | |||||
| GG | 156 (66.1) | 285 (75.4) | 1.000 (reference) | ||
| GA | 68 (28.8) | 82 (21.7) | 0.652 (0.447–0.951) | 0.026 | 0.039 |
| AA | 12 (5.1) | 11 (2.9) | 0.506 (0.218–1.174) | 0.113 | 0.338 |
| Dominant (GG vs. GA+AA) | 0.630 (0.441–0.901) | 0.011 | 0.017 | ||
| Recessive (GG+GA vs. AA) | 0.564 (0.244–1.300) | 0.179 | 0.536 | ||
| G allele | 380 (80.5) | 652 (86.2) | 1.000 (reference) | ||
| A allele | 92 (19.5) | 104 (13.8) | 0.654 (0.481–0.891) | 0.007 | 0.011 |
| HWE P | 0.208 | 0.095 | |||
| VEGF 1725G>A | |||||
| GG | 199 (84.3) | 348 (92.1) | 1.000 (reference) | ||
| GA | 34 (14.4) | 30 (7.9) | 0.503 (0.299–0.848) | 0.010 | 0.029 |
| AA | 3 (1.3) | 0 (0.0) | N/A | 0.995 | 0.995 |
| Dominant (GG vs. GA+AA) | 0.462 (0.277–0.772) | 0.003 | 0.010 | ||
| Recessive (GG+GA vs. AA) | N/A | 0.993 | 0.993 | ||
| G allele | 432 (91.5) | 726 (96.0) | 1.000 (reference) | ||
| A allele | 40 (8.5) | 30 (4.0) | 0.446 (0.273–0.726) | 0.001 | 0.004 |
| HWE P | 0.273 | 0.422 |
Abbreviations: RPL, recurrent pregnancy loss; HWE, Hardy–Weinberg Equilibrium. a Adjusted by age of female participants. b False discovery rate-adjusted p-value for multiple hypotheses testing using the Benjamini–Hochberg method. Acceptance of statistical significance at p < 0.05 and 95% CI not including 1.